Romosozumab--aqqg

(Evenity®)

Evenity®

Drug updated on 11/14/2023

Dosage FormInjection (subcutaneous: 105 mg/1.17 mL)
Drug ClassSclerostin inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Evenity (romosozumab-aqqg) Prescribing Information.2020Amgen

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials (CDM-J).2023Pharmacoepidemiology & Drug Safety
Clinical and pharmacoeconomic combined report: romosozumab. 2022CADTH
Importance of time point–specific indirect treatment comparisons of osteoporosis treatments: a systematic literature review and network meta-analyses. 2022Clinical Therapeutics
Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review.2022Journal of Clinical Densitometry
Romosozumab versus teriparatide for the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis through a grade analysis of evidence. 2021Orthopaedic Surgery
Antiresorptive and anabolic medications used in the perioperative period of patients with osteoporosis undergoing spine surgery: their impact on the biology of fusion and systematic review of the literature. 2021Journal of Neurosurgery
A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis.2021Osteoporosis International
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.2020NIHR
Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: a reanalysis of the meta-analysis.2020Bone
Risk of falls in postmenopausal women treated with romosozumab: preliminary indices from a meta-analysis of randomized, controlled trials.2020Osteoporosis and Sarcopenia
Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data.2020Osteoporosis International
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta-analysis.2020Bone
Safety of romosozumab in osteoporotic men and postmenopausal women: a meta-analysis and systematic review. 2020Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
Assessment report: evenity. 2020EMA
Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).2019Menopause
Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis.2019The Journal of Clinical Endocrinology and Metabolism
Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials.2019Maturitas
Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials.2019BMC Musculoskeletal Disorders

Clinical Practice Guidelines